搜索筛选:
搜索耗时0.0862秒,为你在为你在102,285,761篇论文里面共找到 4 篇相符的论文内容
发布年度:
Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet(扶正化瘀片) and Entecavir:Design of a Randomized,Dou
[期刊论文] 作者：LI Zheng-xin,ZHAO Zhi-min,LIU Ping,ZHENG Qing-shan,LIU Cheng-hai,
来源：中国结合医学杂志（英文版） 年份：2021
Background:Antiviral therapy can lead to regression of fibrosis in chronic hepatitis B (CHB),but it has a limited effect on cirrhosis.Chinese medicines (CMs),particularly Fuzheng Huayu Tablet(扶正化瘀片,FZHY),have an antifibrotic effect in ......
A multicenter,phase III trial of hemocoagulase Agkistrodon:hemostasis,coagulation,and safety in pati
[期刊论文] 作者：JIA Zhen-geng,HE Xiao-dong,WAN Yuan-lian,WANG Shan,XIU Dian-rong,TANG Yun,LI Jie,XU Jing-yong,ZHENG Qing-shan,
来源：中华医学杂志（英文版） 年份：2010
Background Hemocoagulase Agkistrodon for injection is a single component thrombin which has passed phases I and II clinical trials. The purpose of this phase II...
A Phase Ⅰ Study Comparing the Pharmacokinetics,Safety and Immunogenicity of Infliximab Biosimilar GB
[会议论文] 作者：WANG Qian,WANG Yi-tong,LV Jie,AN You-zhong,DONG Li-hou,CHENG Hui-yang,REN Sheng-bin,WANG Qian,ZHENG Qing-shan,
来源：2018年中国药学会药物临床评价研究专业委员会学术年会暨临床研究高峰论坛 年份：2018
Purpose: To compare the pharmacokinetics(PK),safety and immunogenicity of GB242 as a potential biosimilar infliximab with infliximab reference products in healthy Chinese subjects....
[会议论文] 作者：,ZU Li-an,WANG Qian,WANG Qi,WANG Wei,WANG Yi-tong,ZANG Yan-nan,XIE Zhen-wei,CHEN Shi,WANG Mei,ZHENG Qing-shan,
来源：2018年中国药学会药物临床评价研究专业委员会学术年会暨临床研究高峰论坛 年份：2018
Objective T0001 is the first mutant of etanercept known to exhibit a higher affinity to tumor necrosis factor α(TNF-α)than etanercept.In order to investigate the safety and tolerability of T0001 in th...
相关搜索：
